Published in Drug Saf on October 01, 2013
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf (2014) 1.13
Similarity-based modeling applied to signal detection in pharmacovigilance. CPT Pharmacometrics Syst Pharmacol (2014) 0.94
Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med (2010) 4.32
Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med (2012) 3.26
Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med (2009) 2.80
Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc (2011) 2.65
Desideratum for evidence based epidemiology. Drug Saf (2013) 1.99
A two-way messaging system to enhance antiretroviral adherence. J Am Med Inform Assoc (2003) 1.89
Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol (2013) 1.83
The role of data mining in pharmacovigilance. Expert Opin Drug Saf (2005) 1.81
Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med (2013) 1.72
Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform (2009) 1.68
Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc (2010) 1.62
When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf (2012) 1.45
Accelerating statistical research in drug safety. Pharmacoepidemiol Drug Saf (2006) 1.39
Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res (2011) 1.14
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf (2014) 1.13
A comparison of the empirical performance of methods for a risk identification system. Drug Saf (2013) 1.12
Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform (2012) 1.10
An evaluation of three signal-detection algorithms using a highly inclusive reference event database. Drug Saf (2009) 1.10
Issues in applied statistics for public health bioterrorism surveillance using multiple data streams: research needs. Stat Med (2007) 1.08
Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf (2012) 1.03
Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.99
Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.99
Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med (2010) 0.98
Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics (2013) 0.96
Bayesian logistic injury severity score: a method for predicting mortality using international classification of disease-9 codes. Acad Emerg Med (2008) 0.94
A Sequential Monte Carlo Method for Bayesian Analysis of Massive Datasets. Data Min Knowl Discov (2003) 0.92
Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Methodol (2012) 0.92
Complement factor H 402H variant and reticular macular disease. Arch Ophthalmol (2011) 0.88
Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain (2013) 0.88
Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf (2013) 0.87
Assessment of case definitions for identifying acute liver injury in large observational databases. Drug Saf (2013) 0.85
The impact of injury coding schemes on predicting hospital mortality after pediatric injury. Acad Emerg Med (2009) 0.83
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Int Clin Psychopharmacol (2015) 0.82
Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.82
Patterns in nursing home medication errors: disproportionality analysis as a novel method to identify quality improvement opportunities. Pharmacoepidemiol Drug Saf (2010) 0.82
Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.81
Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.81
Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf (2013) 0.81
Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey. Drug Saf (2013) 0.81
Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature. Biostatistics (2013) 0.80
Dynamic logistic regression and dynamic model averaging for binary classification. Biometrics (2011) 0.79
Managing data quality for a drug safety surveillance system. Drug Saf (2013) 0.79
Large-scale parametric survival analysis. Stat Med (2013) 0.79
High-dimensional, massive sample-size Cox proportional hazards regression for survival analysis. Biostatistics (2013) 0.78
Design and validation of a data simulation model for longitudinal healthcare data. AMIA Annu Symp Proc (2011) 0.77
Authors' reply to Hennessy and Leonard's comment on "Desideratum for evidence-based epidemiology". Drug Saf (2015) 0.75
Quantitative signal detection for vaccines. Hum Vaccin (2010) 0.75
Response to comment on 'empirical assessment of methods for risk identification in healthcare data'. Stat Med (2013) 0.75
Atypical Antipsychotics and the Risk of Falls and Fractures Among Older Adults: An Emulation Analysis and an Evaluation of Additional Confounding Control Strategies. J Clin Psychopharmacol (2017) 0.75
The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system. Drug Saf (2013) 0.75
Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Saf (2007) 0.75
Bayesian methods for design and analysis of safety trials. Pharm Stat (2013) 0.75